PT Kimia Farma Tbk (IDX: KAEF)
Health Care · Pharmaceuticals · ID
Rp442.00
+0.45% today · -14.2% 1Y
PT Kimia Farma Tbk (IDX: KAEF) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $139.39M and employs 9,361 people.
Over the last twelve months the share price has lost 14.2%, trading between 380.00 and 785.00.
Tweenvest scores PT Kimia Farma Tbk across four factors: quality 44/100, value 53/100, growth 0/100. Its strongest factor is value.
KAEF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $139.39M
- Revenue (TTM)
- $534.16M
- P/E
- —
- EPS
- -41.25
- Dividend yield
- —
- Beta (5Y)
- 1.04
- 52-week high
- Rp785.00
- 52-week low
- Rp380.00
- Avg volume (3M)
- —
- Shares outstanding
- 5.57B
- Employees
- 9,361
- Next earnings
- —
About PT Kimia Farma Tbk
PT Kimia Farma (Persero) Tbk, an Indonesian entity, is engaged in the manufacturing and sale of a diverse range of products, including pharmaceuticals, herbal remedies, iodine, salts, quinine and its derivatives, and vegetable oils. Its business operations are structured across several key divisions: Manufacturing, Distribution, Retail, and Other Services. Beyond these, the company's portfolio extends to the production and sale of generic, ethical, licensed, and narcotic pharmaceuticals, along with over-the-counter drugs, medical equipment, raw materials, and cosmetics. Its extensive distribution network ensures products reach various outlets, including pharmacies, hospital pharmacies, medical centers, and drugstores. Established in 1817, the company maintains its headquarters in Jakarta, Indonesia.
- ISIN
- ID1000070303
- Founded
- 1817
- Listed since
- Jul 5, 2001
- Exchange
- Indonesia Stock Exchange
- Currency
- IDR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.70 | -0.02% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.19 | -0.68% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.90 | +0.16% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.90 | +0.13% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.72 | +0.51% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.99 | +0.07% |
Figures last refreshed Aug 18, 2026.